UKHSA urges parents and carers to take these simple steps to ensure children make the healthiest start to the New Year
The UK Health Security Agency is reminding parents and carers of the simple steps they can take to ensure their children make the healthiest start to the new school term. The new year brings with it an opportunity to teach children about the importance of good hygiene and with the recent increase in cases of flu and high levels of other viruses such as norovirus, it’s more important than ever.
The latest surveillance data from UKHSA shows that flu activity continued to increase over the Christmas break, with hospitalisations also increasing. Flu is now circulating at high levels in the community, an increase on the levels we saw before the school holidays, which is why it’s especially important to reinforce good hygiene habits as children return to school.
Figures are expected to rise further as children go back to school and many parents return to the workplace. However, there are simple steps that all families can take to reduce the spread of these infections and protect households and classrooms from illness this New Year.
Teaching good hygiene habits
Parents are encouraged to lead by example and encourage good hygiene habits such as using a tissue to catch coughs and sneezes, as well as washing hands.
Regularly washing your hands with soap and warm water for 20 seconds, or using hand sanitiser when convenient, is one of the most effective ways to stop the spread of germs. Alcohol gels don’t kill all bugs so don’t rely on these.
Knowing when to keep your child at home and when to send them to school
January marks the start of a new term, with new things to learn and friends to make. Time off school can disrupt learning and also inconvenience parents and carers having to stay off work. This is why it’s important to know when to keep your child at home and when to send them to school.
Children can stay in school with symptoms such as a runny nose, sore throat or slight cough if otherwise well and do not have a high temperature but should stay home if they’re displaying symptoms such as having a fever. If your child has diarrhoea and vomiting, they should stay home for at least 48 hours after these symptoms clear up.
If you have symptoms of flu or COVID-19 such as a high temperature, cough and feeling tired and achy, try to limit your contact with others. If you have symptoms and need to leave the house, you should consider wearing a face covering.
Stopping the spread of stomach bugs
Stomach bugs spread easily in schools, nurseries and households. If you or your child have diarrhoea and vomiting, washing your hands with soap and warm water and using bleach-based products to clean surfaces will help stop infections from spreading.
Alcohol gels do not kill off norovirus so soap and warm water is best. Don’t prepare food for others if you have diarrhoea or vomiting or for 48 hours after symptoms stop. If you are unwell, you should also avoid visiting people in hospitals and care homes to avoid passing on the infection to those who are more vulnerable. Do not to return to school, nursery or work until 48 hours after symptoms have stopped.
Getting vaccinated
Flu vaccination helps to protect against infection and severe disease. Although it is late in the programme, if you are eligible and not yet vaccinated, you can still take up your offer of immunisation.
Last year, falling vaccination rates among young children resulted in a widespread measles outbreak in England, which is why it’s important to check your children are up-to-date with their routine vaccinations, which protect against diseases such as measles, mumps, rubella, diphtheria and polio. If parents are unsure of their child’s vaccination status, they can check their child’s red book or contact their local GP.
If you are pregnant, it’s also important that you take up all vaccinations offered to you, including whooping cough and the new RSV vaccine which protects newborn babies against serious illness.
Dr Richard Pebody, Director, Clinical & Emerging Infections at UKHSA, said: “It’s an important time of year, as children get started on the new school term.
“There are simple steps you can take to help stop the spread of nasty illness in the next few weeks of winter, including making sure your child is regularly washing their hands, knowing when to keep your child off school and ensuring they are up to date with vaccinations.”
Public urged to prevent further ‘new year spread’ by following good hygiene and taking up ‘final chance’ vaccines where still available
Latest data from the UK Health Security Agency shows the anticipated increase in flu activity over the festive season, as people are urged to protect themselves this New Year.
The overall weekly hospital admission rate for influenza increased to 14.09 per 100,000 in week 52, compared with 10.69 per 100,000 the previous week (51) and 8.72 per 100,000 in week 50.
Vaccination offers the best protection against serious illness and hospitalisation, particularly for those who are vulnerable or elderly. While the national booking system for flu vaccination closed on 19 December, eligible groups are reminded that they can still book their vaccination through their GP surgery or local pharmacy where available.
Flu is currently at high levels and often circulates for many weeks through the course of winter. Vaccination will provide those eligible with the best protection.
Professor Susan Hopkins, Chief Medical Advisor at the UK Health Security Agency, said: “For many of us, the festive period is marked with parties and socialising with friends and family, meaning it’s not unusual to see an increase in flu at this time of year and this was anticipated.
“This is why we have been urging those eligible to take up a free flu vaccine. The good news if you did, is that you are less likely to be severely affected by flu. If you’re still offered a vaccine through local services, you should take it up as we could see high levels for some weeks still. This is particularly important if you’re a health and social care worker, as we know these services are under significant winter pressures right now.
“If you have symptoms of flu or COVID-19 such as a high temperature, cough and feeling tired and achy, try to limit your contact with others, especially those who are vulnerable.
“If you have symptoms and need to leave the house, our advice remains that you should wear a face covering. Washing hands regularly and using and disposing tissues in bins can reduce the spread of respiratory illnesses.”
UKHSA’s surveillance bulletin shows that COVID-19 levels decreased over the festive period, with RSV also decreasing. Although COVID-19 is currently circulating at low levels, this could change in the coming winter months. Vaccination against RSV is being offered for the first time to anyone who is 28 or more weeks pregnant, along with people aged 75 to 79 years.
‘We have detected a single confirmed human case of Clade Ib mpox. This is the first detection of this Clade of mpox in the UK, the wider risk to the UK population remains low’.
The UK Health Security Agency (UKHSA) has detected a single confirmed human case of Clade Ib mpox. The risk to the UK population remains low.
This is the first detection of this Clade of mpox in the UK. It is different from mpox Clade II that has been circulating at low levels in the UK since 2022, primarily among gay, bisexual and other men-who-have-sex-with-men (GBMSM).
UKHSA, the NHS and partner organisations have well tested capabilities to detect, contain and treat novel infectious diseases, and while this is the first confirmed case of mpox Clade Ib in the UK, there has been extensive planning underway to ensure healthcare professionals are equipped and prepared to respond to any confirmed cases.
The case was detected in London and the individual has been transferred to the Royal Free Hospital High Consequence Infectious Diseases unit. They had recently travelled to countries in Africa that are seeing community cases of Clade Ib mpox. The UKHSA and NHS will not be disclosing any further details about the individual.
Close contacts of the case are being followed up by UKHSA and partner organisations. Any contacts will be offered testing and vaccination as needed and advised on any necessary further care if they have symptoms or test positive.
UKHSA is working closely with the NHS and academic partners to determine the characteristics of the pathogen and further assess the risk to human health.
While the existing evidence suggests mpox Clade Ib causes more severe disease than Clade II, we will continue to monitor and learn more about the severity, transmission and control measures. We will initially manage Clade Ib as a high consequence infectious disease (HCID) whilst we are learning more about the virus.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: “It is thanks to our surveillance that we have been able to detect this virus. This is the first time we have detected this Clade of mpox in the UK, though other cases have been confirmed abroad.
“The risk to the UK population remains low, and we are working rapidly to trace close contacts and reduce the risk of any potential spread. In accordance with established protocols, investigations are underway to learn how the individual acquired the infection and to assess whether there are any further associated cases.”
Health and Social Care Secretary Wes Streeting, said: “I am extremely grateful to the healthcare professionals who are carrying out incredible work to support and care for the patient affected.
“The overall risk to the UK population currently remains low and the government is working alongside UKHSA and the NHS to protect the public and prevent transmission.
“This includes securing vaccines and equipping healthcare professionals with the guidance and tools they need to respond to cases safely.
“We are also working with our international partners to support affected countries to prevent further outbreaks.”
Steve Russell, NHS national director for vaccination and screening, said: “The NHS is fully prepared to respond to the first confirmed case of this clade of mpox.
“Since mpox first became present in England, local services have pulled out all the stops to vaccinate those eligible, with tens of thousands in priority groups having already come forward to get protected, and while the risk of catching mpox in the UK remains low, if required the NHS has plans in place to expand the roll out of vaccines quickly in line with supply.”
Clade Ib mpox has been widely circulating in the Democratic Republic of Congo (DRC) in recent months and there have been cases reported in Burundi, Rwanda, Uganda, Kenya, Sweden, India and Germany.
Clade Ib mpox was detected by UKHSA using polymerase chain reaction (PCR) testing.
Common symptoms of mpox include a skin rash or pus-filled lesions which can last 2 to 4 weeks. It can also cause fever, headaches, muscle aches, back pain, low energy and swollen lymph nodes.
The infection can be passed on through close person-to-person contact with someone who has the infection or with infected animals and through contact with contaminated materials. Anyone with symptoms should continue to avoid contact with other people while symptoms persist.
The UK has an existing stock of mpox vaccines and last month announced further vaccines are being procured to support a routine immunisation programme to provide additional resilience in the UK. This is in line with more recent independent JCVI advice.
Working alongside international partners, UKHSA has been monitoring Clade Ib mpox closely since the outbreak in DRC first emerged, publishing regular risk assessment updates.
The wider risk to the UK population remains low.
UKHSA has published its first technical briefing on clade I mpox which provides further information on the current situation and UK preparedness and response.
Ensuring Scotland is prepared as mpox cases increase in Central and Eastern Africa
With the World Health Organization declaring a recent rise in mpox cases in Central and Eastern Africa a Public Health Emergency of International Concern, Dr Kirsty Roy and Dr Kate Smith, Consultants in Public Health at PHS, explain more about the current international situation and what is being done to prepare for any cases seen in Scotland:
The recent rise of mpox cases in Central and Eastern Africa is of global concern due to the potential for the virus to spread beyond the affected countries. It’s therefore important that we’re prepared in the event a case is identified in Scotland.
Mpox is an uncommon viral infection compared to viruses like influenza or COVID-19.
It typically causes a blistering rash which can last 2 to 4 weeks and can be accompanied by fever, headaches, muscle and back aches, tiredness and swollen lymph nodes.
There are two main types of mpox – clade 1 and clade 2 that are then further divided into clade 1a, clade 1b and clade 2b. Each type can differ in who they affect, how they spread, and the severity of the outcomes.
Clade 1 mpox is more serious than clade 2, as it can be passed on more easily, can make people more severely ill, and has a higher fatality rate. This is why clade 1 is classified as a high consequence infectious disease (HCID). HCIDs are rare in the UK, and established protocols and guidance are in place to manage these.
What’s the current global situation?
Historically, clade 1 mpox has been associated with Central Africa and linked with more severe disease and higher death rates. Recently, a new type (clade 1b) has emerged and is circulating, particularly in sexual networks in the Democratic Republic of Congo (DRC) and neighboring countries.
It was the emergence and rapid spread of clade 1b that prompted the World Health Organization to declare the outbreak as a Public Health Emergency of International Concern (PHEIC) in August 2024.
Although most cases are currently confined to Central and Eastern Africa, there is the potential for the virus to spread out with the continent to other countries, as we saw with the global outbreak of mpox clade 2 in 2022.
It’s therefore important to be aware of the above symptoms. Anyone with these should stay at home, avoid close contact with others and get medical help by phone. More information can be found on NHS inform.
How is mpox passed on?
Mpox is not passed on very easily between people. However, you can get it from close contact with an infected person, including during sex or by contact with contaminated materials (for example bedding or towels).
It’s possible that mpox may also be passed on through close and prolonged contact that can include talking, breathing, coughing or sneezing. There is currently limited evidence around this, and information will be updated when new evidence becomes available.
What’s the current situation in Scotland?
Currently, no cases of clade 1 mpox have been confirmed in Scotland. The UK Health Security Agency (UKHSA) confirmed it had detected the first case of mpox clade 1b in England on 30 October, however, the risk to the UK population is still considered low.
PHS is working closely with public health partners across the UK, as well as NHS boards, to monitor the situation and prepare for any cases of clade 1 mpox in Scotland.
As part of this, we have rapidly put testing in place to ensure suspected cases can be quickly tested in Scotland at the Edinburgh Specialist Virology Centre (SVC) and the West of Scotland Specialist Virology Centre (WoSSVC) Glasgow.
What’s the travel advice?
Currently the risk to most travellers is small. A list of countries where cases of Clade 1 mpox have been identified can be found on the UK Government website
Anyone travelling to an affected country is encouraged to take precautions, such as minimising physical or sexual contact – especially with individuals showing signs of a rash – to reduce the risk of infection.
Working in partnership with Scottish airports, we have ensured that information about the clade 1b international situation is visible to travellers in Scottish Airports. These signpost to key information on affected countries and how to access healthcare services in Scotland if an individual develops mpox symptoms.
Is there a vaccine to protect against mpox?
Mpox belongs to a family of viruses that includes smallpox and a vaccine that was developed to protect against smallpox is also considered effective against mpox.
This vaccine was used as part of the response to the 2022 outbreak of clade 2 mpox, which mainly affected gay, bisexual or other men who have sex with men (GBMSM), and Scotland continues to offer mpox vaccination to those at greatest risk.
On behalf of Scotland, and other devolved nations, the UK Government has procured more mpox vaccine doses to strengthen the UK preparedness against clade 1 mpox. More information about vaccine eligibility can be found on NHS inform.
Scotland has a robust public health intelligence system, is now able to rapidly identify and test potential cases and has a supply of effective vaccines. There is also public health information available to ensure people are prepared if they are visiting an area of higher risk. These should all ensure Scotland is prepared should cases emerge within the country.
UKHSA is working with partners to investigate a Shiga toxin-producing E. coli (STEC) outbreak
As of 3 July, there have been a further 13 cases associated with the recent outbreak of STEC O145 since the last update on 27 June. This brings the total number of confirmed cases to 288 in the UK.
All currently confirmed cases had symptom onset dates before 10 June.
Although case reporting rates are continuing to decline, we expect to see an additional small number of cases linked to this outbreak as further samples are referred to us from NHS laboratories and whole genome sequencing is conducted.
Confirmed case totals:
191 in England
62 in Scotland
31 in Wales
4 in Northern Ireland (evidence suggests that they acquired their infection in England)
Based on information from 263 cases to date, 49% were admitted to hospital.
Amy Douglas, Incident Director at UKHSA, said: “It’s encouraging that reported cases are continuing to decline, however we still expect to see a few more cases linked to this outbreak as further samples are referred to us for testing.
“Symptoms of infections with STEC include severe and sometimes bloody diarrhoea, stomach cramps, vomiting and fever. While diarrhoea and vomiting can have a range of causes, there are simple steps you can take to reduce your risk and the risk of infecting others.
“Washing your hands with soap and warm water and using disinfectants to clean surfaces will help stop any further spread of infection. If you are unwell, you should not prepare food for others while unwell and avoid visiting people in hospitals or care homes to avoid passing on the infection in these settings.
“Do not return to work, school or nursery until 48 hours after your symptoms have stopped. If you are concerned about your symptoms, follow NHS.UK guidance on when to seek help and the steps you can take to avoid further spread to family and friends.”
Darren Whitby, Head of Incidents at the Food Standards Agency, said: “The food chain investigation into this outbreak will continue to take account of any new information as it becomes available.
“We will continue to work with the relevant businesses, local authorities and agencies involved to ensure the necessary steps are in place to protect consumers.!
As cases linked to this outbreak are now low and continue to decline, this week’s update (5 July) will be the final weekly report on case numbers unless there is a significant change.
UKHSA is working with partners to investigate a Shiga toxin-producing E. coli (STEC) outbreak
As of 25 June, there have been a further 19 cases associated with the recent outbreak of STEC O145 since the last update a week ago, bringing the total number of confirmed cases to 275 in the UK.
All currently confirmed cases had symptom onset dates before 4 June. Although case reporting rates are declining, we expect to see more cases linked to this outbreak as further samples are referred to us from NHS laboratories and whole genome sequencing is conducted.
Confirmed case totals:
182 in England
58 in Scotland
31 in Wales
4 in Northern Ireland (evidence suggests that they acquired their infection in England)
Based on information from 249 cases to date, 49% were admitted to hospital.
Through surveillance, UKHSA has identified 2 individuals in England who died within 28 days of infection with the STEC outbreak strain.
Based on the information available from health service clinicians one of these deaths is likely linked to their STEC infection. Both individuals had underlying medical conditions. The deaths occurred in May.
Amy Douglas, Incident Director at UKHSA, said: “We’re pleased that fewer cases have been reported, however we still expect to see a few more cases linked to this outbreak as further samples are referred to us for testing.
“Symptoms of infections with STEC include severe and sometimes bloody diarrhoea, stomach cramps, vomiting and fever. While diarrhoea and vomiting can have a range of causes, there are simple steps you can take to reduce your risk and the risk of infecting others.
“Washing your hands with soap and warm water and using disinfectants to clean surfaces will help stop any further spread of infection. If you are unwell, you should not prepare food for others while unwell and avoid visiting people in hospitals or care homes to avoid passing on the infection in these settings. Do not return to work, school or nursery until 48 hours after your symptoms have stopped.
“If you are concerned about your symptoms, follow NHS.UK guidance on when to seek help and the steps you can take to avoid further spread to family and friends.”
Darren Whitby, Head of Incidents at the FSA said: “Earlier this month, we confirmed that several sandwich manufacturers had taken precautionary action to withdraw and recall various sandwiches, wraps, subs and rolls after food chain and epidemiological links enabled us to narrow down a wide range of foods to a type of lettuce used in sandwich products as the likely cause of the outbreak.
“This remains a complex investigation and we continue to work with the relevant businesses and the local authorities to ensure necessary steps are being taken to protect consumers.
“Although we are confident in the likely source of the outbreak being linked to lettuce, work continues to confirm this and identify the root cause of the outbreak with the growers, suppliers and manufacturers so that actions can be taken to prevent a re-occurrence.”
UKHSA and ONS have published the latest data from the Winter Coronavirus (COVID-19) Infection Study, known as the Winter CIS
Winter COVID-19 Infection Study shows a continued decline in COVID-19 in England and Scotland.
The latest data from the Winter COVID-19 Infection Study, an epidemiological study run in partnership by the UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS), shows a clear decline in the prevalence of SARS-CoV-2 in England and Scotland in the 2 weeks up to 10 January.
Analysis by UKHSA suggests that prevalence in the community is 2.3%, or around one in every 43 people. This represents a decrease in prevalence from 3.1% (one in every 32 people) in the previous report.
Positivity data from the ONS indicates that of the approximately 26,000 participants who reported LFD test results in the last reporting period, 1.9% tested positive for COVID-19, compared to 2.7% in the last report.
The most recent data shows a clear decline in prevalence in Scotland and most of the regions in England. This decline was also observed for the age groups between 18 to 74.
Professor Steven Riley, Director General for Data and Surveillance at UKHSA said: “This week’s data confirms the early signs of a decline in COVID-19 across the country that we saw in last week’s report.
“While this is welcome, it is important to recognise that this does not mean that the risk of becoming ill with COVID-19 has gone away.
“In previous years, we have sometimes seen a decline in early January followed by an increase over the next few weeks, so it remains important that we continue to do what we can to reduce transmission.
“Those people who are most at risk of severe illness from COVID-19 can still receive a seasonal vaccination until the end of this month, and we urge anyone eligible who has not already done so to come forward. You can get a vaccine through your GP, by booking with a local NHS vaccination service, or you can find a COVID-19 vaccination walk-in site.
“If you are showing symptoms of COVID-19 or other respiratory illnesses, you should try to limit your contact with other people as much as possible, especially those who are older or more vulnerable.”
Since the beginning of 2023, the number of extensively-antibiotic resistant Shigella cases has increased by 53%. Much of this increase has been driven by a cluster of extensively-antibiotic resistant Shigella sonnei, of which there have been 97 cases in 2023 (up to and including November), compared to just 4 cases last year.
The strain is difficult to treat because it does not respond to the antibiotics typically used to treat Shigella. Cases have been diagnosed in all regions of England, but cases are concentrated in London (45), the North West (21) and South East (12).
In January 2022, there was a similar rise in cases of extensively antibiotic-resistant Shigella sonnei infections caused by another outbreak strain.
Cases of Shigella have been rising since the easing of COVID-19 restrictions in July 2021, with annual cases now higher than the average before the pandemic. The month with the highest number of reported Shigella diagnoses prior to the COVID-19 pandemic was 392 in September 2019, which increased to 485 in September 2023 – representing a 24% increase.
Shigella is a gut infection that causes diarrhoea (sometimes mixed with blood), stomach cramps and fever. It is caused by bacteria found in faeces.
It can be passed on through the faecal-oral route during sex, either directly or via unwashed hands and only a tiny amount of bacteria can spread the infection. Symptoms are typically seen between 1 and 4 days after exposure and are commonly mistaken for food poisoning.
Dr Gauri Godbole, Consultant Medical Microbiologist at UKHSA, said: “This is a concerning rise in cases of this antibiotic resistant strain, meaning treatment can be very difficult.
“One of the best ways to protect yourself and your partners is to practice good hygiene after sex. Avoid oral sex immediately after anal sex, and change condoms between anal or oral sex and wash your hands with soap after sexual contact.
“It’s important that gay, bisexual, and other men who have sex with men (GBMSM) do not dismiss their symptoms and speak to their GP or sexual health clinic, mentioning Shigella, if they are unwell.
“GBMSM with Shigella may have been exposed to other sexually transmitted infections (STIs) including HIV, so a sexual health screen at a clinic or ordering tests online is recommended.”
Shigella is very infectious. Although symptoms can be unpleasant, in most cases they will subside within a week, but some individuals need hospitalisation and require intravenous antibiotic treatment. Effective antibiotic treatments are limited for this extremely resistant strain.
Antibiotic treatment is recommended in cases with severe symptoms, those requiring hospital admission, those with prolonged diarrhoea (beyond 7 days) or in those who have underlying immunodeficiency.
If you have been diagnosed with Shigella, give yourself time to recover. Keep hydrated and get lots of rest. Don’t have sex until 7 days after your last symptom and avoid spas, swimming, jacuzzis, hot tubs and sharing towels as well as preparing food for other people until a week after symptoms stop.
Reducing transmission is key to protecting more vulnerable groups. You can find out more information about Shigella and get advice on other topics at Sexwise or by calling the free National Sexual Health Helpline at 0300 123 7123.
COVID-19 case rates continued to increase this week compared to our previous report. A total 9.7% of 4,288 respiratory specimens reported through the Respiratory DataMart System were identified as COVID-19. This is compared to 7.1% of 4,303 from the previous report.
The overall COVID-19 hospital admission rate for week 34 was 3.37 per 100,000 population, an increase from 3.00 per 100,000 in the previous report.
Intensive care units (ICU) admission rates have increased to 0.11 per 100,000 compared to 0.08 per 100,000 in the previous report.
Hospital admission rates have increased in most age groups.
Those aged 85 years and over continue to have the highest hospital admission rates; these have increased to 34.15 per 100,000 from 32.63 per 100,000 in the previous report. Admission rates among those aged 75 to 84 years have increased to 17.66 per 100,000 from 15.71 per 100,000 in the previous report.
Dr Mary Ramsay, Head of Immunisation at the UK Health Security Agency (UKHSA), said: “Over the last 2 weeks, we have seen an increase in some COVID-19 indicators. This includes hospital admissions and ICU admissions, but these have all stabilised over the last week. While case rates have continued to rise, rates remain low overall, and we will continue to monitor them closely.
“If you are experiencing any symptoms of respiratory illness, you should avoid mixing with other people, especially those who are vulnerable. This will help combat the spread of COVID-19.
“This week, the Department of Health and Social Care (DHSC) announced that the winter vaccination programme has been brought forwardas a precautionary measure to deliver greater protection against the potential impact of BA.2.86 variant. We urge everyone eligible to take up the vaccine when offered.”
New BA.2.86 variant found in Scotland
Scotland has detected its first case of a new Covid variant that is being closely monitored by the World Health Organization.
The BA.2.86 variant is not yet considered a variant of concern but it has a high number of mutations.
Scotland’s winter vaccination programme starts on 4 September, but in response to the new cases PHS and Scottish government are now working to bring winter vaccinations forward for those at the highest risk of becoming seriously ill from flu and Covid-19.
The UK Health Security Agency (UKHSA) has published an initial risk assessment of the SARS-CoV-2 variant BA.2.86.
This variant was detected in the UK yesterday (Friday 18 August), and has also been identified in Israel, Denmark and the US. It has been designated as V-23AUG-01 for the purpose of UKHSA monitoring.
The newly identified variant has a high number of mutations and is genomically distant from both its likely ancestor, BA.2, and from currently circulating XBB-derived variants.
There is currently one confirmed case in the UK in an individual with no recent travel history, which suggests a degree of community transmission within the UK. Identifying the extent of this transmission will require further investigation.
There is currently insufficient data to assess the relative severity or degree of immune escape compared to other currently-circulating variants.
Dr Meera Chand, Deputy Director, UKHSA said: “V-23AUG-01 was designated as a variant on 18 August 2023 on the basis of international transmission and significant mutation of the viral genome. This designation allows us to monitor it through our routine surveillance processes.
“We are aware of one confirmed case in the UK. UKHSA is currently undertaking detailed assessment and will provide further information in due course.”
UKHSA will continue to monitor the situation closely and will publish the results of our analysis when they are available.
Testing to be based on clinical need in hospitals, care homes and prisons
Routine COVID-19 testing in hospitals, care homes and prisons is to be substantially reduced following clinical and scientific advice.
Due to the success of the vaccination programme and improved treatments, Public Health Scotland and Antimicrobial Resistance & Healthcare Associated Infection Scotland have recommended a return to pre-pandemic testing.
This means testing will be based on person-centred clinical decisions, rather than a routine policy for all individuals. Routine testing will continue for patients moving from hospitals to care homes and will be reviewed based on future advice and outbreaks. Tests will also continue to be available for those eligible for antiviral treatment.
The new guidance will come into effect by 30 August 2023.
Chief Medical Officer Professor Sir Gregor Smith said: “Due to the success of vaccines in protecting people, and the availability of improved treatments, now is the right time to revise the advice on routine COVID-19 testing across health and social care settings and prisons. This will ensure the testing regime remains effective and proportionate.
“Routine testing will remain when patients are discharged from hospital to care homes, to provide additional reassurance for these settings, and testing will still be required when clinically appropriate.
“The clinical advice tells us that focusing on the risk to individuals under general infection control procedures will allow our hospital, social care and prison staff to better protect those in their care and that there is no longer a requirement to apply separate COVID-19 guidance across the board when so many are now protected from its worst harms.”
COVID CASES ON THE RISE
This UK Health Security Agency fortnightly flu and COVID-19 report brings together the latest surveillance data along with the latest public health advice.
The latest report was produced on 3 August:
COVID-19 case rates continued to increase this week compared to our previous report. 5.4% of 4,396 respiratory specimens reported through the Respiratory DataMart System were identified as COVID-19. This is compared to 3.7% of 4,403 from the previous report.
The overall COVID-19 hospital admission rate for week 30 was 1.97 per 100,000 population, an increase from 1.17 per 100,000 in the previous report.
ICU admission rates have decreased to 0.05 compared to 0.07 in the previous report.
Those aged 85 years and over continue to have the highest hospital admission rates; these have increased to 20.49 per 100,000 from 9.8 per 100,000 in the previous report.
Admission rates among those aged 75 to 84 years have increased to 9.45 per 100,000 from 5.54 in the previous report.
Dr Mary Ramsay, Head of Immunisation at the UK Health Security Agency (UKHSA), said: “We continue to see a rise in COVID-19 cases in this week’s report. We have also seen a small rise in hospital admission rates in most age groups, particularly among the elderly.
“Overall levels of admission still remain extremely low and we are not currently seeing a similar increase in ICU admissions. We will continue to monitor these rates closely.Regular and thorough hand washing helps protect you from COVID-19 and other bugs and viruses.
“If you have symptoms of a respiratory illness, we recommend staying away from others where possible.
“The NHS will be in contact in autumn 2023 when the seasonal vaccine is available for those who are eligible due to health conditions or age, and we urge everyone who is offered to take up the vaccine when offered.”